Clinical trial
Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma
NCT00335647 · Immune Control, Industry · Completed
Key facts
| NCT number | NCT00335647 |
|---|---|
| Title | Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma |
| Official title | A Phase I/IIa, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerance, and Preliminary Activity of Intravenous High-Dose Fluphenazine HCI in Patients With Advanced Multiple Myeloma |
| Lead sponsor | Immune Control, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | fluphenazine hydrochloride |
| Enrollment | 30 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2008 |
| First posted | Jun 12, 2006 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: